Traditionally, herbal supplements have shown an exceptional potential of desirability for the prevention of diseases and their treatment. Sulforaphane (SFN), an organosulfur compound belongs to the isothiocyanate (ITC) group and is mainly found naturally in cruciferous vegetables. Several studies have now revealed that SFN possesses broad spectrum of activities and has shown extraordinary potential as antioxidant, antitumor, anti-angiogenic, and anti-inflammatory agent. In addition, SFN is proven to be less toxic, non-oxidizable, and its administration to individuals is well tolerated, making it an effective natural dietary supplement for clinical trials. SFN has shown its ability to be a promising future drug molecule for the management of various diseases mainly due to its potent antioxidant properties. In recent times, several newer drug delivery systems were designed and developed for this potential molecule in order to enhance its bioavailability, stability, and to reduce its side effects. This review focuses to cover numerous data supporting the wide range of pharmacological activities of SFN, its drug-related issues, and approaches to improve its physicochemical and biological properties, including solubility, stability, and bioavailability. Recent patents and the ongoing clinical trials on SFN are also summarized.
Background:
Gefitinib, a tyrosine kinase inhibitor, is effectively used in the targeted
treatment of malignant conditions. It suppresses the signal transduction cascades leading to cell
proliferation in the tumors and is now currently approved in several countries globally as secondline and third-line treatment for non-small cell lung cancer (NSCLC).
Objective:
This review is aimed to summarize the journey of gefitinib as an established anticancer
drug for the management of various cancers. Moreover, this review will focus on the mechanism
of action, established anticancer activities, combination therapy, nanoformulations, as well as recent clinical trials and patents on gefitinib
Methods:
The data for this review was collected from scientific databases such as PubMed, Science Direct, Google Scholar, etc. Recent patents on gefitinib granted in the last two years were
collected from databases Patentscope, USPTO, Espacenet, InPASS and Google Patents. Data for
the recent clinical trials were obtained from the U.S. National Library of Medicine database.
Results:
Recent pre-clinical and clinical studies during the period 2015-2021 demonstrating the
efficacy of gefitinib were selected and summarized. Total 31 patents were granted in the year
2020-2021 concerning gefitinib. The efficacy of gefitinib against lung cancer, as well as other
cancer types, including breast, prostate, colon, cervix etc., was reviewed.
Conclusion:
Gefitinib showed significant advantages in being more effective, safer and more stable, and the associated biopharmaceutical problems are addressed by the application of nanotechnology. The combination therapy using gefitinib and various anticancer molecules of natural and
synthetic origin has shown an improved anticancer profile.
Graphene, owing to its unique chemical structure and extraordinary chemical, electrical, thermal, optical, and mechanical properties, has opened up a new vista of applications, specifically as novel sensing platforms. The last decade has seen an extensive exploration of graphene and graphene-based materials either alone or modified with nanoparticles and polymers for the fabrication of nanoscale biosensors. These biosensors displayed excellent conductivity, high sensitivity, and selectivity, good accuracy, and precision, rapid detection with low detection limits as well as long-term stability. The unmatched properties of graphene and graphene-based materials have been applied for the detection of a number of chemical and biological molecules successfully for the diagnosis of a variety of diseases, pathogens, and biomarkers of the diseases. This review is aimed to cover the fabrication methods, functionalization techniques, and biomedical applications along with the recent advancements in the field of development of graphene-based biosensors. Recent clinical trials and patents as well as market trends and opportunities associated with graphene-based biosensors are also summarized. The application of graphene-based biosensors in the detection of SARS-CoV-2 causing COVID-19 is also reviewed.
Quercetin (QCT) is an effective antioxidant, antifibrotic and wound healing agent. Silver nanoparticles (AgNPs) are an effective antimicrobial, antifungal and wound healing agent and considered as gold standard for wound treatment especially diabetic and burn wounds. The present study aimed to investigate QCT loaded AgNPs in hydrogel matrices (QCT-AgNPs hydrogel) as synergistic treatment paradigms for diabetic wound. Quality by Design approach was employed for the optimization of hydrogel preparation using carbopol-934 and aloevera. The developed QCT-AgNPs hydrogel was characterized for hydrodynamic diameter, %entrapment efficiency (%EE), surface morphology, texture analysis, in-vitro drug release, skin irritation study, ex-vivo permeation study (confocal study), and antimicrobial efficacy. The optimized formulation showed hydrodynamic diameter of ∼44.1 nm with smooth spherical surface morphology and ∼92.09% of QCT was entrapped in QCT-AgNPs hydrogel matrices. The antimicrobial study revealed superior therapeutic efficacy of QCT-AgNPs hydrogel in comparison to marketed (MRKT) gel on S. aureus and E. coli. Moreover, in-vivo results demonstrated that QCT-AgNPs hydrogel significantly (p < 0.001) reduced the wound gap and increased % re-epithelialization compared with diabetic control after 18 d of post treatment in excisional diabetic wound model. In conclusion, this study opens up an avenue for the treatment of diabetic wound.
Aim: This study aims to load tamoxifen (TAM) and sulforaphane (SFN) into nanostructured lipid carriers (NLCs) to enhance their oral delivery. Materials & methods: TAM-SFN-NLCs were prepared using Precirol® ATO5 and Transcutol® HP, characterized and evaluated in vitro and ex vivo to assess the drug release profile and intestinal permeability, respectively. In vivo pharmacokinetic and acute toxicity assessment was performed in Wistar rats. Results: Optimized TAM-SFN-NLCs exhibited a particle size of 121.9 ± 6.42 nm and zeta potential of -21.2 ± 2.91 mV. The NLCs enhanced intestinal permeability of TAM and SFN and augmented oral bioavailability of TAM and SFN 5.2-fold and 4.8-fold, respectively. SFN significantly reduced TAM-associated toxicity in vivo. Conclusion: This coencapsulation of a chemotherapeutic agent with a herbal bioactive in NLCs could pave a novel treatment approach against cancer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.